NICE recommends Mimpara with caveats

The National Institute for Health and Clinical Excellence (NICE), the UK advisory body responsible for evaluating the effectiveness of drugs and clinical treatments in England and Wales, has issued guidance on the use of Amgen's first-in-class oral calcimimetic, Mimpara (cinacalcet), in the treatment of secondary hyperparathyroidism in end-stage renal disease on maintenance dialysis therapy.

The NICE did not recommend Mimpara for the routine treatment of secondary hyperparathyroidism in patients with end-stage kidney disease on dialysis but for refractory secondary hyperparathyroidism in patients with end-stage kidney disease who have very high levels of parathyroid hormone in their blood that cannot be lowered by other treatments, and cannot have an operation to remove the parathyroid glands because of the risks involved. The NICE recommends that Mimpara patients should have regular checks and that treatment should be stopped if blood parathyroid hormone levels do not fall within four months.